Use of pridopidine for the treatment of fragile x syndrome
AssigneesPrilenia Neurotherapeutics Ltd., National University of Singapore, Agency for Science, Technology and Research
InventorsMichael HAYDEN, Mahmoud Abdulhossein POULADI
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Claims18
A method of treating a subject afflicted with fragile X syndrome (FXS), comprising administering to the subject a pharmaceutical composition comprising an amount of pridopidine or pharmaceutical acceptable salt thereof, effective to treat the subject.
A therapeutic package for dispensing to, or for use in dispensing to, a subject afflicted with fragile X syndrome (FXS), which comprises:
- a) one or more unit doses, each such unit dose comprising an amount of pridopidine, wherein the amount of said pridopidine in said unit dose is effective, upon administration to said subject, to treat the subject, and
- b) a finished pharmaceutical container therefor, said container containing said unit dose or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of said subject.
A therapeutic package for dispensing to, or for use in dispensing to, a subject afflicted with fragile X syndrome (FXS), wiich comprises:
- a) one or more unit doses, each such unit dose comprising:
- i. an amount of pridopidine and
- ii. an amount of one or more of a second pharmaceutical agent selected from the group consisting of Carbamazepine, Valproic acid, Divalproex, Lithium carbonate, Gabapentin, Lamotrigine, Topiramate, Tiagabine, Vigabatrin, Phenobarbital, Primidone, Phenytoin, Methylphenidate, Dextroamphetamine, L-acetylcarnitine, Venlafaxine, Nefazodone, Amantadine, Folic acid, Clonidine, Guanfacine, Fluoxetine, Sertraline, Citalopram, Paroxetine, Fluvoxamine, Risperidone, Quetiapine, Olanzapine, Trazodone, and Melatonin,
- b) wherein the respective amounts of one or more of the second pharmaceutical agent in said unit dose are effective, upon concomitant administration to said subject, to treat the subject, and
- c) a finished pharmaceutical container therefor, said container containing said unit dose or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of said subject.
Dependencies are inferred from the claim text.